<DOC>
	<DOC>NCT00440986</DOC>
	<brief_summary>The purpose of study is to determine the best and durable choice of treatment between phlebotomy and eritrocytoapheresis in the medium- and long-term clinical management of HH</brief_summary>
	<brief_title>Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis</brief_title>
	<detailed_description>Patients affected by Hereditary hemochromatosis need a completeinitial staging of disease, a correct clinical management, a good chance of treatment and long-term follow-up. Clinical manifestations at presentation and during follow-up may consistently vary according to diagnostic criteria, treatment options and follow-up durability, up to the interruption. So, 25 caucasian patients, 16 males and 6 females of age &gt;18 yrs. have been consecutively diagnosed and randomly included into two arms of treatment, phlebotomy vs. eritrocytoapheresis, evaluating, at baseline and 6-12-18-24-36 months, the clinical status concerning liver, kidney, pancreas, heart, endocrine iron overload and function and final outcome related to therapeutic strategy, including the cost/effectiveness analysis</detailed_description>
	<mesh_term>Hemochromatosis</mesh_term>
	<criteria>Patiens newly diagnosed having Hereditary Hemochromatosis Age &lt; 18 yrs. Not obese (BMI &lt;30) Not consuming alchol beverages, Not affected by systemic diseases and known hepatic viruses</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Clinical Management</keyword>
	<keyword>Phlebotomy</keyword>
	<keyword>Eritrocytoapheresis</keyword>
</DOC>